Æterna Zentaris Inc. (AEZS)

1.88
0.01 0.53
NASDAQ : Health Technology
Prev Close 1.89
Open 1.90
Day Low/High 1.85 / 1.91
52 Wk Low/High 0.78 / 3.75
Volume 49.91K
Avg Volume 748.90K
Exchange NASDAQ
Shares Outstanding 9.94M
Market Cap 30.94M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

IIROC Trade Resumption - AEZS; BNE

IIROC Trade Resumption - AEZS; BNE

IIROC Trading Halt - AEZS

IIROC Trading Halt - AEZS

Aeterna Zentaris Reports Third Quarter 2017 Financial And Operating Results

Aeterna Zentaris Reports Third Quarter 2017 Financial And Operating Results

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company"), a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies, today reported financial and operating...

Aeterna Zentaris To Announce Third Quarter 2017 Financial And Operating Results On November 8, 2017

Aeterna Zentaris To Announce Third Quarter 2017 Financial And Operating Results On November 8, 2017

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company") will announce its third quarter 2017 financial and operating results after market close on Wednesday, November 8, 2017.

Aeterna Zentaris Announces Appointment Of Interim Chief Financial Officer

Aeterna Zentaris Announces Appointment Of Interim Chief Financial Officer

Aeterna Zentaris Inc. (NASDAQ & TSX: AEZS) a specialty biopharmaceutical company (the "Company") announced effective today, September 25, 2017, that Jeffrey Whitnell has been appointed to the position of Interim Chief...

Aeterna Zentaris Announces Departure Of Vice President, Finance & Chief Accounting Officer

Aeterna Zentaris Announces Departure Of Vice President, Finance & Chief Accounting Officer

Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the "Company") announced today the departure of the Company's Vice President, Finance & Chief Accounting Officer, Geneviéve Lemaire, effective on or before...

Aeterna Zentaris Reports Second Quarter 2017 Financial And Operating Results

Aeterna Zentaris Reports Second Quarter 2017 Financial And Operating Results

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company"), a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies, today reported financial and operating...

IIROC Trade Resumption - AEZS

IIROC Trade Resumption - AEZS

Aeterna Zentaris Engages Advisors And Provides Update To Shareholders

Aeterna Zentaris Engages Advisors And Provides Update To Shareholders

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company"), announced today that the special committee of independent directors (the "Strategic Review Committee") has engaged a consulting firm and a financial...

IIROC Trading Halt - AEZS

IIROC Trading Halt - AEZS

Aeterna Zentaris To Announce Second Quarter 2017 Financial And Operating Results On August 10, 2017

Aeterna Zentaris To Announce Second Quarter 2017 Financial And Operating Results On August 10, 2017

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company") will announce its second quarter 2017 financial and operating results after market close on Thursday, August 10, 2017.

Aeterna Zentaris Commences Legal Action Against David Dodd And Philip Theodore

Aeterna Zentaris Commences Legal Action Against David Dodd And Philip Theodore

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company"), announced today that it has filed a claim against the Company's former CEO David Dodd and its former General Counsel Philip Theodore (the "Defendants")...

Aeterna Zentaris Forms Strategic Review Committee And Appoints Michael Ward As CEO

Aeterna Zentaris Forms Strategic Review Committee And Appoints Michael Ward As CEO

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company"), announced today that it has formed a special committee of independent directors (the "Strategic Review Committee") to consider and evaluate various...

NDA For Macrilen™ For The Evaluation Of Growth Hormone Deficiency In Adults Granted December 30, 2017 PDUFA Date

NDA For Macrilen™ For The Evaluation Of Growth Hormone Deficiency In Adults Granted December 30, 2017 PDUFA Date

Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the "Company") today announced that it has been notified by the U.

Aeterna Zentaris Resubmits NDA For Macrilen™ For The Evaluation Of Growth Hormone Deficiency In Adults

Aeterna Zentaris Resubmits NDA For Macrilen™ For The Evaluation Of Growth Hormone Deficiency In Adults

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company") today announced that it has resubmitted a new drug application ("NDA") to the U.

Aeterna Zentaris To Present At 2017 Marcum MicroCap Conference

Aeterna Zentaris Inc. (TSX: AEZS) (NASDAQ: AEZS) (the "Company") today announced that the Company's President and Chief Executive Officer, David Dodd, will present a corporate overview at the 2017 Marcum MicroCap Conference...

Aeterna Zentaris Announces Election Of Directors At 2017 Shareholders' Meeting

Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the "Company"), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today...

Aeterna Zentaris Reports First Quarter 2017 Financial And Operating Results

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company"), a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies, today reported financial and operating...

Aeterna Zentaris To Announce First Quarter 2017 Financial And Operating Results On May 8, 2017

Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the "Company") will announce its first quarter 2017 financial and operating results after market close on Monday, May 8, 2017.

Tech Leads Nasdaq to a New Record; Congressional Funding Bill Boosts S&P 500

Tech Leads Nasdaq to a New Record; Congressional Funding Bill Boosts S&P 500

Wall Street ended its first session of May mostly higher as tech stocks boosted the Nasdaq and a congressional funding deal brought relief to the S&P 500.

Stocks Trade Higher, Financial Stocks on Watch After Trump Talks Banks

Stocks Trade Higher, Financial Stocks on Watch After Trump Talks Banks

Stocks are mostly higher on Monday after congressional leaders reach a deal to fund the federal government through the rest of the budget year.

Stocks Move Higher, Nasdaq at Records as Congress Makes Funding Deal

Stocks Move Higher, Nasdaq at Records as Congress Makes Funding Deal

Stocks turn green again on Monday morning after congressional leaders reach a deal to fund the federal government through the rest of the budget year.

Aeterna Zentaris Announces That ZoptEC Phase 3 Clinical Study Of Zoptrex™ Did Not Achieve Its Primary Endpoint

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (the "Company") today announced that the ZoptEC Phase 3 clinical study of Zoptrex™ (zoptarelin doxorubicin) in women with locally advanced, recurrent or metastatic...

Aeterna Zentaris To Announce Top-Line Results Of The ZoptEC Phase 3 Clinical Study Of Zoptrex™

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company") will announce the top-line results of the ZoptEC Phase 3 clinical study of Zoptrex™ (zoptarelin doxorubicin) in women with locally advanced, recurrent...

Aeterna Zentaris Announces Replacement At The Market Issuance Program

Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the "Company") announced today that it has entered into a new At Market Issuance Sales Agreement, dated April 27, 2017 (the "New ATM Sales Agreement"), with H.

TheStreet Quant Rating: E+ (Sell)